HCV病毒血症肾脏移植的使用趋势与1年结局
该研究利用美国国家登记数据,分析2015年4月至2019年3月期间HCV病毒血症肾脏的使用趋势,并采用匹配方法比较移植后1年eGFR。结果显示,至2019年第一季度,多数HCV病毒血症肾脏移植给了HCV血清学阴性受者,其1年eGFR与匹配的非病毒血症肾脏相似,且受者HCV血清状态未导致临床显著的肾功能差异。
要点
- HCV血清学阴性受者接受HCV病毒血症肾脏的比例逐年上升。
- 匹配后,HCV病毒血症肾脏与对照肾脏的1年eGFR相似。
- 受者HCV血清状态与1年eGFR无临床显著差异。
核心结论
- 到2019年,HCV血清学阴性患者接受了大多数HCV病毒血症供肾。
- 常用器官质量评分基于1年移植肾功能低估了HCV病毒血症肾脏的质量。
- 使用HCV病毒血症肾脏时,受者HCV血清状态与短期移植肾功能无关。
研究设计与样本
- 研究使用美国国家登记数据,分析2015年4月1日至2019年3月31日期间HCV病毒血症肾脏的使用趋势。
- 采用高级匹配方法比较相似肾脏移植给高度相似受者后的eGFR。
主要发现
- 2019年第一季度,200个HCV病毒血症肾脏移植给HCV血清学阴性受者,69个移植给HCV血清学阳性受者,105个被丢弃。
- HCV病毒血症肾脏的丢弃概率随时间下降。
- 愿意接受HCV血清学阳性肾脏的候选者从2936人增至16809人。
- 在HCV血清学阴性受者中,匹配器官质量预测因子后,HCV病毒血症肾脏与HCV非病毒血症肾脏的1年eGFR相似(66.3 vs 67.1 ml/min per 1.73 m2,P=0.86)。
- HCV病毒血症肾脏移植后,受者HCV血清状态与1年eGFR差异无统计学意义(66.5 vs 71.1 ml/min per 1.73 m2,P=0.056)。
临床怎么用
- 可考虑将HCV病毒血症肾脏移植给HCV血清学阴性受者,短期移植肾功能与对照相似。
- 器官质量评分可能低估HCV病毒血症肾脏,应结合1年移植肾功能评估。
局限性
- 研究为观察性设计,可能存在残余混杂。
- 随访时间限于1年,缺乏长期结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent pilot trials have demonstrated the safety of transplanting HCV-viremic kidneys into HCV-seronegative recipients. However, it remains unclear if allograft function is impacted by donor HCV-viremia or recipient HCV-serostatus. METHODS: We used national United States registry data to examine trends in HCV-viremic kidney use between 4/1/2015 and 3/31/2019. We applied advanced matching methods to compare eGFR for similar kidneys transplanted into highly similar recipients of kidney transplants. RESULTS: Over time, HCV-seronegative recipients received a rising proportion of HCV-viremic kidneys. During the first quarter of 2019, 200 HCV-viremic kidneys were transplanted into HCV-seronegative recipients, versus 69 into HCV-seropositive recipients, while 105 HCV-viremic kidneys were discarded. The probability of HCV-viremic kidney discard has declined over time. Kidney transplant candidates willing to accept a HCV-seropositive kidney increased from 2936 to 16,809 from during this time period. When transplanted into HCV-seronegative recipients, HCV-viremic kidneys matched to HCV-non-viremic kidneys on predictors of organ quality, except HCV, had similar 1-year eGFR (66.3 versus 67.1 ml/min per 1.73 m2, P=0.86). This was despite the much worse kidney donor profile index scores assigned to the HCV-viremic kidneys. Recipient HCV-serostatus was not associated with a clinically meaningful difference in 1-year eGFR (66.5 versus 71.1 ml/min per 1.73 m2, P=0.056) after transplantation of HCV-viremic kidneys. CONCLUSIONS: By 2019, HCV-seronegative patients received the majority of kidneys transplanted from HCV-viremic donors. Widely used organ quality scores underestimated the quality of HCV-viremic kidneys based on 1-year allograft function. Recipient HCV-serostatus was also not associated with worse short-term allograft function using HCV-viremic kidneys.
引用
- Potluri VS, Goldberg DS, Mohan S, et al. National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys. J Am Soc Nephrol. 2019. PMID: 31515244. doi:10.1681/ASN.2019050462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。